Upjohn Business(1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted(2) Results
Full-Year 2020 Revenues of $41.9 Billion, Which Now Exclude Upjohn(1), Reflect 3% Operational Growth; When the Impact from Consumer Healthcare(1) and the $154 Million of Sales of BNT162b2 are Excluded, Full-Year 2020 Revenues Grew 8% Operationally –Operational Growth Primarily Driven by Strong Performances from Vyndaqel/Vyndamax, Eliquis, Oncology Biosimilars, Ibrance, Prevenar 13 Outside of the U.S., Inlyta, Xeljanz and Xtand
Fourth-Quarter2020 Revenues of $11.7 Billion, Reflecting 11% Operational Growth; Excluding Sales of BNT162b2, Revenues Grew 9% Operationally
Full-Year 2020 Reported Diluted EPS(3) of $1.71, Adjusted Diluted EPS(2) of $2.22; Fourth-Quarter2020Reported Diluted EPS(3) of $0.10, Adjusted Diluted EPS(2) of $0.42
Raises Full-Year 2021 Guidance(4)for Adjusted Diluted EPS(2) to a range of $3.10-$3.20 and Provides 2021 Financial Guidance(4) forOther Adjusted(2) Income Statement Line Items
Achieved Clinical Trial Success Rates of 48% in Phase 1, 52% in Phase 2, 85% in Phase 3 and an End-to-End Clinical Success Rate of 21%, All of Which Exceeded the Industry Averages(5
NEW YORK, NY, Tuesday, February 2, 2021 – Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter2020 and full-year 2020, raised 2021 guidance(4)for Adjusted diluted EPS(2) and provided 2021 financial guidance(4) forother Adjusted(2) income statement line items, including details regarding the expected contributions to 2021 performance from BNT162b2, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine.
EXECUTIVE COMMENTARYDr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2020 has been a transformational year, not only for Pfizer, but also in the life of every patient in every community that we serve. As a company, we saw the culmination of Pfizer’s decade-long conversion into a pure-play, science and innovation-focused company. Right away, our ability to move quickly and utilize cutting-edge science tohelp address the world’s most important medical challenges was put to the test by the COVID-19 pandemic. Our record-breaking success at developing a vaccine against COVID-19, along with our partner BioNTech, is just one example of what we believe this new Pfizer is capable of achieving. As the world looks forward to 2021 with renewed hope for better days ahead, we also look forward with renewed confidence and resolve in our ability to fulfill our purpose, to deliver breakthroughs that change patients’ lives.”
Frank D’Amelio, Chief Financial Officer and Executive Vice President, Global Supply, stated: “I am very pleased with how our company performed in 2020, and particularly in the fourth quarter, where we achieved double digit operational revenue growth driven by a wide range of products and geographies, including growth within allof our therapeutic areas. I was also pleased that Pfizer completed the transaction to combine Upjohn with Mylan to form Viatrisin the fourth quarter, which I believe positions both Pfizer and Viatris for a bright future. I feelconfident in our ability to continue to perform well and deliver on our commitments in 2021 and beyond, both to our patients and to our shareholders.”
